Konruns(SH:603590) Zhong Guo Jing Ji Wang·2025-09-08 07:33Core Viewpoint - Kangchen Pharmaceutical (603590.SH) announced a share reduction plan by its controlling shareholder Liu Jianhua due to personal funding needs, intending to reduce up to 4,780,693 shares, which is no more than 3% of the total shares [1][2]. Summary by Relevant Sections Share Reduction Plan - Liu Jianhua plans to reduce his holdings through centralized bidding and block trading methods, with a total reduction not exceeding 4,780,693 shares [1][2]. - The reduction will occur within three months after a 15 trading day period following the announcement, excluding any legally prohibited reduction periods [1]. - The maximum number of shares that can be reduced via centralized bidding is 1% of the total shares within any consecutive 90-day period, while block trading can account for up to 2% [1][2]. Financial Implications - Based on the closing price of 56.93 yuan on September 5, the total amount from the planned reduction is approximately 272 million yuan [2]. Company Background - Kangchen Pharmaceutical was listed on the Shanghai Stock Exchange on August 27, 2018, with an initial issuance of 40 million shares, representing 25% of the total shares post-IPO [3]. - The company raised a total of 973.6 million yuan, with a net amount of 891.43 million yuan intended for various projects, including innovative drug research and production capacity expansion [3].